These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1024 related articles for article (PubMed ID: 12090977)

  • 1. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
    Baum M; Budzar AU; Cuzick J; Forbes J; Houghton JH; Klijn JG; Sahmoud T;
    Lancet; 2002 Jun; 359(9324):2131-9. PubMed ID: 12090977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU;
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    ; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
    Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
    Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
    Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
    Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
    Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
    J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Buzdar A
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S42-8. PubMed ID: 12756078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
    ; Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker GY; Nabholtz JM
    Lancet Oncol; 2006 Aug; 7(8):633-43. PubMed ID: 16887480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of anastrozole in adjuvant therapy for postmenopausal patients.
    Buzdar AU
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):21-9. PubMed ID: 14613023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
    Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
    Boccardo F; Rubagotti A; Guglielmini P; Fini A; Paladini G; Mesiti M; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii10-4. PubMed ID: 16760270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anastrozole: in early breast cancer.
    Wellington K; Faulds DM
    Drugs; 2002; 62(17):2483-90; discussion 2491-2. PubMed ID: 12421108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Buzdar AU
    Clin Cancer Res; 2004 Jan; 10(1 Pt 2):355S-61S. PubMed ID: 14734491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.